Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC1 | P33527 | 2/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | ACLY | P53396 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | ACACA | Q13085 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PRNP | P04156 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.39 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16817608 | 0.84 | MAPT (0.49) | ABCC1ABCG2LMNAMAPK1ACACB | |
| SCHEMBL1098305 | 0.83 | MEN1 (0.41) | ABCC1ABCG2LMNAMAPK1ACACB | |
| SCHEMBL16817403 | 0.83 | FABP4 (0.53) | ABCC1ABCG2LMNAMAPK1MEN1 | |
| SCHEMBL14317217 | 0.82 | MAPT (0.46) | MAPK1MEN1NPC1GAARAB9A | |
| SCHEMBL7414469 | 0.82 | PTGDR2 (0.42) | ABCC1ABCG2LMNAACACBACACA | |
| SCHEMBL3494188 | 0.81 | MAPT (0.42) | ABCC1ABCG2LMNAMAPK1ACACB | |
| SCHEMBL8329259 | 0.80 | ABCC1 (0.63) | ABCC1ABCG2ACLYLMNAMAPK1 | |
| SCHEMBL3495969 | 0.80 | METAP1 (0.42) | ABCC1ABCG2ACACBACACAMEN1 | |
| SCHEMBL3493608 | 0.80 | METAP1 (0.45) | ABCC1ABCG2LMNAACACBACACA | |
| SCHEMBL7426935 | 0.79 | CYP1A2 (0.39) | ABCC1ABCG2ACACBACACAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934280-B2 | Condensed thiophene derivatives useful as NaPi-IIb inhibitors | ELI LILLY AND COMPANY (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934280-B2 | Condensed thiophene derivatives useful as NaPi-IIb inhibitors | ELI LILLY AND COMPANY (US) | 2021-03-02 | — | — | US | disclosed |
| CN-109563070-B | Fused thiophene derivatives as NAPI-IIB inhibitors | 伊莱利利公司 | 2021-02-26 | — | — | CN | disclosed |
| EP-3497091-B1 | CONDENSED THIOPHENE DERIVATIVES USEFUL AS NAPI-IIB INHIBITORS | LILLY CO ELI (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200031813-A1 | CONDENSED THIOPHENE DERIVATIVES USEFUL AS NAPI-IIB INHIBITORS | ELI LILLY AND COMPANY | 2020-01-30 | — | — | US | disclosed |
| US-20200031813-A1 | CONDENSED THIOPHENE DERIVATIVES USEFUL AS NAPI-IIB INHIBITORS | ELI LILLY AND COMPANY | 2020-01-30 | — | — | US | disclosed |
| EP-3497091-A1 | CONDENSED THIOPHENE DERIVATIVES USEFUL AS NAPI-IIB INHIBITORS | Eli Lilly and Company (US) | 2019-06-19 | — | — | EP | disclosed |
| WO-2018034883-A1 | CONDENSED THIOPHENE DERIVATIVES USEFUL AS NAPI-IIB INHIBITORS | ELI LILLY AND COMPANY (US) | 2018-02-22 | — | — | WO | disclosed |
| US-9604977-B2 | Bicyclic thiophenylamide compounds | HOFFMAN-LA ROCHE INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604977-B2 | Bicyclic thiophenylamide compounds | HOFFMAN-LA ROCHE INC. (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2861574-B1 | NEW BICYCLIC THIOPHENYLAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| EP-2861574-B1 | NEW BICYCLIC THIOPHENYLAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-20150175594-A1 | NEW BICYCLIC THIOPHENYLAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175594-A1 | NEW BICYCLIC THIOPHENYLAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934280-B2 | Condensed thiophene derivatives useful as NaPi-IIb inhibitors | SLC34A2, ALPI, SLC34A1 | ABCC1 707/4885ABCG2 153/4885ACLY 3323/4885 |
| US-20150175594-A1 | NEW BICYCLIC THIOPHENYLAMIDE COMPOUNDS | NAT1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, BICRA | ABCC1 779/4885ABCG2 8/4885ACLY 1378/4885 |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | ACACA, CPT1B, PC | ABCC1 822/4885ABCG2 1101/4885ACLY 56/4885 |
| US-20200031813-A1 | CONDENSED THIOPHENE DERIVATIVES USEFUL AS NAPI-IIB INHIBITORS | SLC34A2, ALPI, SLC34A1 | ABCC1 707/4885ABCG2 153/4885ACLY 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.